Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study
The Journal of Clinical Endocrinology & Metabolism · 18.12.2024 · 110 (1) · e150-e159
DOI: 10.1210/clinem/dgae130 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 04.03.2024. Verfasst von Arno R Bourgonje und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Net…. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Diabetes Mellitus, Type 2, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dutch Kidney Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Systemic inflammation plays a pivotal role in the development of type 2 diabetes (T2D).
Objective
We hypothesized that circulating levels of calprotectin, a myeloid cell-derived biomarker of inflammation, is associated with the development of new-onset T2D in the general population.
Methods
A total of 4815 initially nondiabetic participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND), a prospective population-based cohort study, were assessed for plasma levels of calprotectin at baseline. Circulating levels of calprotectin were investigated for potential associations with the risk of new-onset T2D, defined as a fasting plasma glucose level of 7.0 mmol/L or greater, a random plasma glucose level of 11.1 mmol/L or greater, a self-reported physician-based diagnosis of T2D, the use of glucose-lowering drugs, or any combinations thereof.
Results
Median plasma calprotectin levels were 0.49 (0.35-0.69) mg/L. Plasma calprotectin levels were significantly associated with the risk of new-onset T2D (hazard ratio [HR] per doubling 1.42 [95% CI, 1.22-1.66]; P < .001). The association remained independent of adjustment for age and sex (HR 1.34 [95% CI, 1.14-1.57]; P < .001), but not after further adjustment for potentially confounding factors (HR 1.11 [95% CI, 0.90-1.37]; P = .326), with adjustment for hyperlipidemia and high-sensitivity C-reactive protein explaining the loss of significance. Stratified analyses showed significant effect modification by hypertension, history of cardiovascular disease (CVD), the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (Pinteraction ≤ .001 for each), and the use of lipid-lowering drugs (Pinteraction ≤ .05), with higher HRs in individuals without hypertension, without history of CVD, with below-median HOMA-IR, and in those not using lipid-lowering drugs.
Conclusion
Elevated plasma levels of calprotectin are associated with a higher risk of developing T2D in the general population and may represent a moveable inflammatory biomarker. This association, however, does not represent a direct effect, and seems dependent on hyperlipidemia and systemic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
- The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
- Department of Internal Medicine, Division of Endocrinology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
- Department of Epidemiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
- Gentian AS, 1596 Moss, Norway.
ORCID-Profile: Arno R Bourgonje, Martin F Bourgonje, Sara Sokooti, Sacha la Bastide-van Gemert, Tom Nilsen, Ron T Gansevoort, Douwe J Mulder, Jan-Luuk Hillebrands, Stephan J L Bakker, André P van Beek, Robin P F Dullaart, Harry van Goor, Amaal E Abdulle
Förderung
- Dutch Kidney Foundation
Zitieren
APA
Bourgonje, A. R., Bourgonje, M. F., Sokooti, S., la Bastide-van Gemert, S., Nilsen, T., Hidden, C., Gansevoort, R. T., Mulder, D. J., Hillebrands, J. L., Bakker, S. J. L., van Beek, A. P., Dullaart, R. P. F., van Goor, H., & Abdulle, A. E. (2024). Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study. The Journal of Clinical Endocrinology & Metabolism, 110(1), e150-e159. https://doi.org/10.1210/clinem/dgae130
Vancouver
Bourgonje AR, Bourgonje MF, Sokooti S, la Bastide-van Gemert S, Nilsen T, Hidden C, et al. Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 2024;110(1):e150-e159. doi:10.1210/clinem/dgae130
BibTeX
@article{Bourgonje2024,
author = {Bourgonje, Arno R and Bourgonje, Martin F and Sokooti, Sara and la Bastide-van Gemert, Sacha and Nilsen, Tom and Hidden, Clara and Gansevoort, Ron T and Mulder, Douwe J and Hillebrands, Jan-Luuk and Bakker, Stephan J L and van Beek, André P and Dullaart, Robin P F and van Goor, Harry and Abdulle, Amaal E},
title = {Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {110},
number = {1},
pages = {e150--e159},
doi = {10.1210/clinem/dgae130}
}
EUVIMED